BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 24926617)

  • 1. p53-directed translational control can shape and expand the universe of p53 target genes.
    Zaccara S; Tebaldi T; Pederiva C; Ciribilli Y; Bisio A; Inga A
    Cell Death Differ; 2014 Oct; 21(10):1522-34. PubMed ID: 24926617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRIAD1 Is a Novel Transcriptional Target of p53 and Regulates Nutlin-3a-Induced Cell Death.
    Lee J; An S; Choi YM; Jung JH; Li L; Meng H; Dong Y; Ahn KJ; An IS; Bae S
    J Cell Biochem; 2017 Jul; 118(7):1733-1740. PubMed ID: 27935098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
    Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
    Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DICER1 regulated let-7 expression levels in p53-induced cancer repression requires cyclin D1.
    Sun X; Tang SC; Xu C; Wang C; Qin S; Du N; Liu J; Zhang Y; Li X; Luo G; Zhou J; Xu F; Ren H
    J Cell Mol Med; 2015 Jun; 19(6):1357-65. PubMed ID: 25702703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nutlin-Induced Apoptosis Is Specified by a Translation Program Regulated by PCBP2 and DHX30.
    Rizzotto D; Zaccara S; Rossi A; Galbraith MD; Andrysik Z; Pandey A; Sullivan KD; Quattrone A; Espinosa JM; Dassi E; Inga A
    Cell Rep; 2020 Mar; 30(13):4355-4369.e6. PubMed ID: 32234473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
    Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
    Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53.
    Sohr S; Engeland K
    Cell Cycle; 2008 Nov; 7(21):3448-60. PubMed ID: 18971636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of new p53 target microRNAs by bioinformatics and functional analysis.
    Bisio A; De Sanctis V; Del Vescovo V; Denti MA; Jegga AG; Inga A; Ciribilli Y
    BMC Cancer; 2013 Nov; 13():552. PubMed ID: 24256616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptome Analysis of Cells Exposed to Actinomycin D and Nutlin-3a Reveals New Candidate p53-Target Genes and Indicates That CHIR-98014 Is an Important Inhibitor of p53 Activity.
    Łasut-Szyszka B; Małachowska B; Gdowicz-Kłosok A; Krześniak M; Głowala-Kosińska M; Zajkowicz A; Rusin M
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
    Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
    J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between p53 and estradiol pathways in transcriptional responses to chemotherapeutics.
    Lion M; Bisio A; Tebaldi T; De Sanctis V; Menendez D; Resnick MA; Ciribilli Y; Inga A
    Cell Cycle; 2013 Apr; 12(8):1211-24. PubMed ID: 23518503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
    Peirce SK; Findley HW
    Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 Suppresses lung resistance-related protein expression through Y-box binding protein 1 in the MCF-7 breast tumor cell line.
    Tian B; Liu J; Liu B; Dong Y; Liu J; Song Y; Sun Z
    J Cell Physiol; 2011 Dec; 226(12):3433-41. PubMed ID: 21344396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological networks and disease functions of RNA-binding protein AUF1.
    Moore AE; Chenette DM; Larkin LC; Schneider RJ
    Wiley Interdiscip Rev RNA; 2014; 5(4):549-64. PubMed ID: 24687816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.
    Drakos E; Atsaves V; Schlette E; Li J; Papanastasi I; Rassidakis GZ; Medeiros LJ
    Leukemia; 2009 Dec; 23(12):2290-9. PubMed ID: 19741726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence.
    Kumamoto K; Spillare EA; Fujita K; Horikawa I; Yamashita T; Appella E; Nagashima M; Takenoshita S; Yokota J; Harris CC
    Cancer Res; 2008 May; 68(9):3193-203. PubMed ID: 18451145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.